PL3360882T3 - 11-hydroksy-6-podstawione pochodne kwasów żółciowych i ich koniugaty aminokwasowe jako modulatory receptorów farnezoidu X - Google Patents

11-hydroksy-6-podstawione pochodne kwasów żółciowych i ich koniugaty aminokwasowe jako modulatory receptorów farnezoidu X

Info

Publication number: PL3360882T3
Authority: PL; Poland
Prior art keywords: farnesoid; hydroxyl; derivatives; substituted; amino acid
Prior art date: 2013-05-14

Application number

PL18163623T

Other languages

English (en)

Inventor

Roberto Pellicciari

Original Assignee

Intercept Pharmaceuticals, Inc.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2013-05-14

Filing date

2014-05-14

Publication date

2021-10-25

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50721801&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL3360882(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2014-05-14 Application filed by Intercept Pharmaceuticals, Inc. filed Critical Intercept Pharmaceuticals, Inc.

2021-10-25 Publication of PL3360882T3 publication Critical patent/PL3360882T3/pl

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/0055—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives
- C07J41/0061—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives one of the carbon atoms being part of an amide group
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
- C07J71/0005—Oxygen-containing hetero ring
- C07J71/001—Oxiranes
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
- C07J9/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
- C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Gastroenterology & Hepatology (AREA)
Urology & Nephrology (AREA)
Pulmonology (AREA)
Steroid Compounds (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

PL18163623T 2013-05-14 2014-05-14 11-hydroksy-6-podstawione pochodne kwasów żółciowych i ich koniugaty aminokwasowe jako modulatory receptorów farnezoidu X PL3360882T3 (pl)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US201361823169P	2013-05-14	2013-05-14
PCT/EP2014/059896 WO2014184271A1 (en)	2013-05-14	2014-05-14	11-hydroxyl-derivatives of bile acids and amino acid conjugates thereof as farnesoid x receptor modulators
EP18163623.4A EP3360882B1 (en)	2013-05-14	2014-05-14	11-hydroxyl-6-substituted-derivatives of bile acids and amino acid conjugates thereof as farnesoid x receptor modulators
EP14723820.8A EP2997035B8 (en)	2013-05-14	2014-05-14	11-hydroxyl-6-substituted-derivatives of bile acids and amino acid conjugates thereof as farnesoid x receptor modulators

Publications (1)

Publication Number	Publication Date
PL3360882T3 true PL3360882T3 (pl)	2021-10-25

Family

ID=50721801

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
PL14723820T PL2997035T3 (pl)	2013-05-14	2014-05-14	11-hydroksy-6-podstawione pochodne kwasów żółciowych i ich koniugaty aminokwasowe jako modulatory receptorów farnezoidu x
PL18163623T PL3360882T3 (pl)	2013-05-14	2014-05-14	11-hydroksy-6-podstawione pochodne kwasów żółciowych i ich koniugaty aminokwasowe jako modulatory receptorów farnezoidu X
PL18163622T PL3360881T3 (pl)	2013-05-14	2014-05-14	11-hydroksy-6-podstawione pochodne kwasów żółciowych i ich koniugaty aminokwasowe jako modulatory receptorów farnezoidowych X

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
PL14723820T PL2997035T3 (pl)	2013-05-14	2014-05-14	11-hydroksy-6-podstawione pochodne kwasów żółciowych i ich koniugaty aminokwasowe jako modulatory receptorów farnezoidu x

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
PL18163622T PL3360881T3 (pl)	2013-05-14	2014-05-14	11-hydroksy-6-podstawione pochodne kwasów żółciowych i ich koniugaty aminokwasowe jako modulatory receptorów farnezoidowych X

Country Status (37)

Country	Link
US (7)	US9611289B2 (pl)
EP (4)	EP3360882B1 (pl)
JP (2)	JP6326131B2 (pl)
KR (1)	KR102229952B1 (pl)
CN (2)	CN105377870B (pl)
AU (1)	AU2014267324B2 (pl)
BR (1)	BR112015028399B1 (pl)
CA (1)	CA2912139C (pl)
CL (2)	CL2015003344A1 (pl)
CR (1)	CR20150643A (pl)
CY (1)	CY1122614T1 (pl)
DK (4)	DK2997035T3 (pl)
EA (1)	EA030152B1 (pl)
ES (4)	ES2671427T3 (pl)
GT (1)	GT201500324A (pl)
HR (1)	HRP20180931T1 (pl)
HU (1)	HUE037996T2 (pl)
IL (2)	IL242555B (pl)
LT (1)	LT2997035T (pl)
MA (1)	MA38647B1 (pl)
ME (1)	ME03082B (pl)
MX (1)	MX352065B (pl)
MY (1)	MY187886A (pl)
NI (1)	NI201500160A (pl)
PE (2)	PE20160665A1 (pl)
PH (1)	PH12015502576B1 (pl)
PL (3)	PL2997035T3 (pl)
PT (3)	PT3360881T (pl)
RS (1)	RS57372B1 (pl)
SA (1)	SA515370140B1 (pl)
SG (1)	SG11201509352XA (pl)
SI (3)	SI3360882T1 (pl)
SM (1)	SMT201800326T1 (pl)
TN (1)	TN2015000497A1 (pl)
TR (1)	TR201809041T4 (pl)
UA (1)	UA118673C2 (pl)
WO (1)	WO2014184271A1 (pl)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1392714B1 (en)	2001-03-12	2005-08-31	Intercept Pharmaceuticals, Inc.	Steroids as agonists for fxr
EP2545964A1 (en)	2011-07-13	2013-01-16	Phenex Pharmaceuticals AG	Novel FXR (NR1H4) binding and activity modulating compounds
PL2997035T3 (pl)	2013-05-14	2018-10-31	Intercept Pharmaceuticals, Inc.	11-hydroksy-6-podstawione pochodne kwasów żółciowych i ich koniugaty aminokwasowe jako modulatory receptorów farnezoidu x
US10301268B2 (en)	2014-03-13	2019-05-28	The Salk Institute For Biological Studies	Analogs of fexaramine and methods of making and using
US10077268B2 (en)	2014-03-13	2018-09-18	Salk Institute For Biological Studies	FXR agonists and methods for making and using
PT3149019T (pt)	2014-05-29	2020-02-19	Bar Pharmaceuticals S R L	Derivados de colano para utilização no tratamento e/ou na prevenção de doenças mediadas por fxr e tgr5/gp-bar1
SG11201703717SA (en)	2014-11-06	2017-06-29	Enanta Pharm Inc	Bile acid analogs an fxr/tgr5 agonists and methods of use thereof
ES2748692T3 (es)	2014-11-19	2020-03-17	Nzp Uk Ltd	Esteroides 6.alfa.-alquil-3,7-diona como intermedios para la producción de moduladores FXR de esteroides
PL3221332T3 (pl)	2014-11-19	2019-10-31	Nzp Uk Ltd	Steroidy, 5.beta.-6-alkilo-7-hydroksy-3-ony jako związki pośrednie do wytwarzania steroidowych modulatorów fxr
KR102527821B1 (ko)	2014-11-19	2023-05-02	엔제트피 유케이 리미티드	스테로이드 FXR 조절인자를 제조하기 위한 중간체로서의 6α-알킬-6,7-다이온 스테로이드
EA033427B1 (ru)	2014-11-19	2019-10-31	Nzp Uk Ltd	6-алкил-7-гидрокси-4-ен-3-оновые стероиды в качестве промежуточных соединений для получения стероидных модуляторов fxr
KR20170099909A (ko)	2014-11-26	2017-09-01	이난타 파마슈티칼스, 인코포레이티드	Fxr/tgr5 작용제로서의 담즙산 유사체 및 이의 이용 방법
US10208081B2 (en)	2014-11-26	2019-02-19	Enanta Pharmaceuticals, Inc.	Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof
US11578097B2 (en)	2014-11-26	2023-02-14	Enanta Pharmaceuticals, Inc.	Tetrazole derivatives of bile acids as FXR/TGR5 agonists and methods of use thereof
MA41094A (fr) *	2014-12-02	2017-10-10	Lilly Co Eli	Procédés de traitement de troubles rénaux
CN105348365A (zh) *	2014-12-03	2016-02-24	四川百利药业有限责任公司	一种胆酸衍生物及其制备方法、药物组合物和用途
CN104523703A (zh) *	2014-12-24	2015-04-22	聂飚	一种游离脂肪酸转运蛋白小分子抑制物的应用
BR112017016766B1 (pt) *	2015-02-06	2023-11-07	Intercept Pharmaceuticals, Inc	Composição compreendendo um agonista fxr e fibrato, bem como uso para tratar doença hepática colestática
CN107249594A (zh)	2015-02-11	2017-10-13	英安塔制药有限公司	作为fxr/tgr5激动剂的胆汁酸类似物及其使用方法
EP3268009A4 (en) *	2015-03-09	2018-12-12	Intercept Pharmaceuticals, Inc.	Methods for modulating bone density
CN107531741A (zh) *	2015-03-10	2018-01-02	美莱斯股份有限公司	氟化和烷基化胆酸
KR20170123658A (ko) *	2015-03-13	2017-11-08	더 솔크 인스티튜트 포 바이올로지칼 스터디즈	장 수용체를 활성화시키는 파네소이드 x 수용체 작용제를 사용한 성인 잠복성 자가면역 당뇨병의 치료
SG10201910670RA (en) *	2015-03-31	2020-01-30	Enanta Pharm Inc	Bile acid derivatives as fxr/tgr5 agonists and methods of use thereof
MA41083A1 (fr) *	2015-04-07	2018-05-31	Intercept Pharmaceuticals Inc	Compositions pharmaceutiques pour thérapie combinée
WO2016168553A1 (en) *	2015-04-17	2016-10-20	Concert Pharmaceuticals, Inc.	Deuterated obeticholic acid
PE20180690A1 (es)	2015-04-27	2018-04-23	Intercept Pharmaceuticals Inc	Composiciones de acido obeticolico y metodos de uso
CN106478759A (zh) *	2015-08-31	2017-03-08	陕西合成药业股份有限公司	奥贝胆酸衍生物及其制备方法和用途
HK1254056A1 (zh)	2015-09-21	2019-07-12	英特塞普特医药品公司	促进肝再生的方法
ES2898705T3 (es) *	2015-10-07	2022-03-08	Intercept Pharmaceuticals Inc	Moduladores de los receptores farnesoides x
JP6924765B2 (ja) *	2016-01-28	2021-08-25	チアタイティエンチンファーマシューティカルグループカンパニーリミテッドChia Tai Tianqing Pharmaceutical Group Co., Ltd.	ステロイド誘導体ｆｘｒ作動薬
WO2017147174A1 (en) *	2016-02-23	2017-08-31	Enanta Pharmaceuticals, Inc.	Heteroaryl containing bile acid analogs as fxr/tgr5 agonists and methods of use thereof
US10364267B2 (en)	2016-02-23	2019-07-30	Enanta Pharmaceuticals, Inc.	Deuterated bile acid derivatives as FXR/TGR5 agonists and methods of use thereof
WO2017147137A1 (en) *	2016-02-23	2017-08-31	Enanta Pharmaceuticals, Inc.	Benzoic acid derivatives of bile acid as fxr/tgr5 agonists and methods of use thereof
PT3426348T (pt) *	2016-03-11	2021-06-28	Intercept Pharmaceuticals Inc	Derivado de 3-desoxi e composições farmacêuticas do mesmo
KR102377338B1 (ko) *	2016-04-13	2022-03-21	인터셉트 파마슈티컬즈, 인크.	암의 치료 방법
GB201608777D0 (en)	2016-05-18	2016-06-29	Dextra Lab Ltd	Compounds
CA3252823A1 (en)	2016-06-13	2025-02-25	Gilead Sciences, Inc.	Fxr (nr1h4) modulating compounds
PL3730487T3 (pl)	2016-06-13	2022-08-16	Gilead Sciences, Inc.	Pochodne azetydyny jako modulatory fxr (nr1h4)
JP7057783B2 (ja)	2016-11-29	2022-04-20	エナンタファーマシューティカルズインコーポレイテッド	スルホニル尿素胆汁酸誘導体の調製方法
US10472386B2 (en)	2017-02-14	2019-11-12	Enanta Pharmaceuticals, Inc.	Bile acid derivatives as FXR agonists and methods of use thereof
EP3585374B1 (en)	2017-02-21	2023-07-19	Genfit	Combination of a ppar agonist with a fxr agonist
SG11201907742YA (en) *	2017-02-23	2019-09-27	Intercept Pharmaceuticals Inc	Pharmaceutical compositions of a bile acid derivative and microbiome and uses thereof
EP4122464B1 (en)	2017-03-28	2024-05-15	Gilead Sciences, Inc.	Therapeutic combinations for treating liver diseases
BR112019020780A2 (pt)	2017-04-07	2020-04-28	Enanta Pharm Inc	processo para preparação de derivados de ácido biliar de carbamato de sulfonila
WO2018226724A1 (en) *	2017-06-05	2018-12-13	Intercept Pharmaceuticals, Inc.	Treatment and prevention of diabetic eye diseases with a bile acid derivatives
AU2018288883B2 (en) *	2017-06-23	2022-06-02	Intercept Pharmaceuticals, Inc.	Methods and intermediates for the preparation of bile acid derivatives
MX2020000873A (es)	2017-07-24	2020-07-22	Intercept Pharmaceuticals Inc	Derivados de ácidos biliares marcados isotópicamente.
GB201812382D0 (en)	2018-07-30	2018-09-12	Nzp Uk Ltd	Compounds
CN109182451B (zh) *	2018-08-21	2021-06-11	四川大学	细胞色素cyp3a7酶的新型特异性探针反应及其应用
PE20211907A1 (es)	2019-01-15	2021-09-28	Gilead Sciences Inc	Compuestos moduladores de fxr (nr1h4)
CA3233305A1 (en)	2019-02-19	2020-08-27	Gilead Sciences, Inc.	Solid forms of fxr agonists
JP2022536060A (ja) *	2019-05-30	2022-08-12	インターセプトファーマシューティカルズ，インコーポレイテッド	胆汁鬱滞性肝疾患の処置で使用するためのｆｘｒアゴニストおよびフィブラートを含む医薬組成物
US20220241376A1 (en)	2019-07-18	2022-08-04	Enyo Pharma	Method for decreasing adverse-effects of interferon
CN110540955B (zh) *	2019-08-28	2021-09-17	北京协同创新研究院	一种提高分化细胞中nrob2基因表达量的方法
IL293892A (en)	2020-01-15	2022-08-01	Inserm Institut National De La Sant? Et De La Rech M?Dicale	Use of fxr agonists for treating an infection by hepatitis d virus
CN117202905A (zh)	2021-01-14	2023-12-08	埃尼奥制药公司	Fxr激动剂和ifn用于治疗hbv感染的协同效果
JP2024517181A (ja)	2021-04-28	2024-04-19	ウエヌイグレックオ・ファーマ	組合せ治療としてｆｘｒアゴニストを使用するｔｌｒ３アゴニストの効果の強い増強
WO2022233398A1 (en) *	2021-05-04	2022-11-10	Kostner Pharma Gmbh	COMPOUNDS FOR REDUCING LIPOPROTEIN(a)
WO2023288123A1 (en)	2021-07-16	2023-01-19	Interecept Pharmaceuticals, Inc.	Methods and intermediates for the preparation of 3.alpha.,7.alpha.,11.beta.-trihydroxy-6.alpha.-ethyl-5.beta.-cholan-24-oic acid
WO2025059651A1 (en) *	2023-09-14	2025-03-20	The Regents Of The University Of California	Bile salt modification to prevent and treat enteric disease

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US2080775A (en) *	1934-08-22	1937-05-18	Celanese Corp	Shedding mechanism for circular looms
US2802775A (en) *	1953-05-29	1957-08-13	Merck & Co Inc	11 alpha-hydroxylation of steroids by aspergillus ochraceus
JPS59205396A (ja) *	1983-05-09	1984-11-20	Kuraray Co Ltd	１１β−ヒドロキシプレグナ−４−エン−３−オン−２０−カルブアルデヒド及びその製造法
ES2326850T3 (es)	1998-12-23	2009-10-20	Glaxo Group Limited	Ensayos para ligandos de receptores nucleares.
ITMI20021532A1 (it) *	2002-07-12	2004-01-12	Roberto Pellicciari	Composti chimici
EP1568706A1 (en) *	2004-02-26	2005-08-31	Intercept Pharmaceuticals, Inc.	Novel steroid agonist for FXR
SI2712617T1 (sl) *	2004-03-12	2017-01-31	Intercept Pharmaceuticals, Inc.	Zdravljenje fibroze z uporabo Fxr ligandov
CA2656320C (en) *	2006-06-27	2015-04-28	Intercept Pharmaceuticals, Inc.	Bile acid derivatives as fxr ligands for the prevention or treatment of fxr-mediated diseases or conditions
PL2997035T3 (pl)	2013-05-14	2018-10-31	Intercept Pharmaceuticals, Inc.	11-hydroksy-6-podstawione pochodne kwasów żółciowych i ich koniugaty aminokwasowe jako modulatory receptorów farnezoidu x

2014
- 2014-05-14 PL PL14723820T patent/PL2997035T3/pl unknown
- 2014-05-14 ES ES14723820.8T patent/ES2671427T3/es active Active
- 2014-05-14 EP EP18163623.4A patent/EP3360882B1/en active Active
- 2014-05-14 HU HUE14723820A patent/HUE037996T2/hu unknown
- 2014-05-14 CN CN201480036949.5A patent/CN105377870B/zh active Active
- 2014-05-14 EP EP20211780.0A patent/EP3848038B1/en active Active
- 2014-05-14 PT PT181636226T patent/PT3360881T/pt unknown
- 2014-05-14 SI SI201431741T patent/SI3360882T1/sl unknown
- 2014-05-14 PL PL18163623T patent/PL3360882T3/pl unknown
- 2014-05-14 PL PL18163622T patent/PL3360881T3/pl unknown
- 2014-05-14 ES ES18163623T patent/ES2843737T3/es active Active
- 2014-05-14 JP JP2016513357A patent/JP6326131B2/ja active Active
- 2014-05-14 TR TR2018/09041T patent/TR201809041T4/tr unknown
- 2014-05-14 EA EA201592055A patent/EA030152B1/ru unknown
- 2014-05-14 SG SG11201509352XA patent/SG11201509352XA/en unknown
- 2014-05-14 ES ES18163622T patent/ES2847002T3/es active Active
- 2014-05-14 LT LTEP14723820.8T patent/LT2997035T/lt unknown
- 2014-05-14 BR BR112015028399-3A patent/BR112015028399B1/pt active IP Right Grant
- 2014-05-14 PT PT181636234T patent/PT3360882T/pt unknown
- 2014-05-14 DK DK14723820.8T patent/DK2997035T3/en active
- 2014-05-14 PE PE2015002397A patent/PE20160665A1/es unknown
- 2014-05-14 DK DK20211780.0T patent/DK3848038T3/da active
- 2014-05-14 UA UAA201511098A patent/UA118673C2/uk unknown
- 2014-05-14 MA MA38647A patent/MA38647B1/fr unknown
- 2014-05-14 WO PCT/EP2014/059896 patent/WO2014184271A1/en not_active Ceased
- 2014-05-14 EP EP18163622.6A patent/EP3360881B1/en active Active
- 2014-05-14 MX MX2015015730A patent/MX352065B/es active IP Right Grant
- 2014-05-14 EP EP14723820.8A patent/EP2997035B8/en active Active
- 2014-05-14 SI SI201431742T patent/SI3360881T1/sl unknown
- 2014-05-14 RS RS20180690A patent/RS57372B1/sr unknown
- 2014-05-14 SI SI201430701T patent/SI2997035T1/sl unknown
- 2014-05-14 KR KR1020157034951A patent/KR102229952B1/ko active Active
- 2014-05-14 DK DK18163622.6T patent/DK3360881T3/da active
- 2014-05-14 DK DK18163623.4T patent/DK3360882T3/da active
- 2014-05-14 ME MEP-2018-159A patent/ME03082B/me unknown
- 2014-05-14 TN TN2015000497A patent/TN2015000497A1/en unknown
- 2014-05-14 PE PE2020000355A patent/PE20200844A1/es unknown
- 2014-05-14 MY MYPI2015002734A patent/MY187886A/en unknown
- 2014-05-14 AU AU2014267324A patent/AU2014267324B2/en active Active
- 2014-05-14 HR HRP20180931TT patent/HRP20180931T1/hr unknown
- 2014-05-14 CN CN201810162562.4A patent/CN108245523B/zh not_active Expired - Fee Related
- 2014-05-14 US US14/120,366 patent/US9611289B2/en active Active
- 2014-05-14 ES ES20211780T patent/ES2936638T3/es active Active
- 2014-05-14 SM SM20180326T patent/SMT201800326T1/it unknown
- 2014-05-14 PT PT147238208T patent/PT2997035T/pt unknown
- 2014-05-14 CA CA2912139A patent/CA2912139C/en active Active
2015
- 2015-11-12 IL IL242555A patent/IL242555B/en active IP Right Grant
- 2015-11-12 SA SA515370140A patent/SA515370140B1/ar unknown
- 2015-11-13 NI NI201500160A patent/NI201500160A/es unknown
- 2015-11-13 PH PH12015502576A patent/PH12015502576B1/en unknown
- 2015-11-13 GT GT201500324A patent/GT201500324A/es unknown
- 2015-11-13 CL CL2015003344A patent/CL2015003344A1/es unknown
- 2015-12-07 CR CR20150643A patent/CR20150643A/es unknown
2016
- 2016-07-15 CL CL2016001809A patent/CL2016001809A1/es unknown
2017
- 2017-02-16 US US15/434,685 patent/US20170216316A1/en not_active Abandoned
2018
- 2018-04-13 JP JP2018077654A patent/JP2018127481A/ja not_active Withdrawn
- 2018-06-01 CY CY20181100583T patent/CY1122614T1/el unknown
- 2018-09-06 US US16/124,139 patent/US10532061B2/en active Active
2019
- 2019-11-26 US US16/695,528 patent/US11000532B2/en active Active
2020
- 2020-02-17 IL IL272718A patent/IL272718B/en active IP Right Grant
2021
- 2021-04-13 US US17/228,819 patent/US20210228599A1/en not_active Abandoned
2023
- 2023-04-03 US US18/295,091 patent/US20230233581A1/en not_active Abandoned
2024
- 2024-08-12 US US18/800,808 patent/US20240398834A1/en active Pending

Also Published As

Publication number	Publication date
ES2847002T3 (es)	2021-07-30
SI3360882T1 (sl)	2021-06-30
TR201809041T4 (tr)	2018-07-23
AU2014267324B2 (en)	2017-11-02
US10532061B2 (en)	2020-01-14
EP3848038A1 (en)	2021-07-14
BR112015028399B1 (pt)	2021-11-16
SI2997035T1 (sl)	2018-10-30
US20230233581A1 (en)	2023-07-27
PE20160665A1 (es)	2016-08-07
LT2997035T (lt)	2018-08-10
EP2997035A1 (en)	2016-03-23
ES2843737T3 (es)	2021-07-20
IL272718B (en)	2020-11-30
JP6326131B2 (ja)	2018-05-16
UA118673C2 (uk)	2019-02-25
WO2014184271A1 (en)	2014-11-20
CL2016001809A1 (es)	2017-01-27
PH12015502576A1 (en)	2016-02-29
PT2997035T (pt)	2018-07-18
DK2997035T3 (en)	2018-07-02
SMT201800326T1 (it)	2018-07-17
JP2016518429A (ja)	2016-06-23
DK3360882T3 (da)	2021-03-08
HUE037996T2 (hu)	2018-09-28
CN105377870B (zh)	2018-04-03
EP2997035B1 (en)	2018-03-28
ME03082B (me)	2019-01-20
US20190209586A1 (en)	2019-07-11
MA38647B1 (fr)	2019-05-31
HRP20180931T1 (hr)	2018-10-05
PL2997035T3 (pl)	2018-10-31
IL242555B (en)	2020-04-30
GT201500324A (es)	2017-09-28
US20210228599A1 (en)	2021-07-29
ES2671427T3 (es)	2018-06-06
US20170216316A1 (en)	2017-08-03
NZ714082A (en)	2021-02-26
TN2015000497A1 (en)	2017-04-06
CA2912139C (en)	2021-04-20
CA2912139A1 (en)	2014-11-20
EP3360882A1 (en)	2018-08-15
US20140371190A1 (en)	2014-12-18
ES2936638T3 (es)	2023-03-21
KR20160007586A (ko)	2016-01-20
CN108245523A (zh)	2018-07-06
US11000532B2 (en)	2021-05-11
HK1221471A1 (zh)	2017-06-02
IL242555A0 (en)	2016-02-01
CN105377870A (zh)	2016-03-02
CN108245523B (zh)	2021-03-26
EP3848038B1 (en)	2022-11-09
EP3360881B1 (en)	2020-12-09
IL272718A (en)	2020-04-30
DK3848038T3 (da)	2023-02-06
EA030152B1 (ru)	2018-06-29
JP2018127481A (ja)	2018-08-16
SA515370140B1 (ar)	2017-04-11
SI3360881T1 (sl)	2021-06-30
SG11201509352XA (en)	2015-12-30
MX352065B (es)	2017-11-08
PH12015502576B1 (en)	2018-09-12
US9611289B2 (en)	2017-04-04
HK1253326A1 (zh)	2019-06-14
PT3360881T (pt)	2021-02-19
US20240398834A1 (en)	2024-12-05
CR20150643A (es)	2016-06-01
PL3360881T3 (pl)	2021-11-15
EP2997035B8 (en)	2018-05-23
CL2015003344A1 (es)	2016-07-15
DK3360881T3 (da)	2021-03-15
BR112015028399A2 (pt)	2017-07-25
NI201500160A (es)	2016-01-04
PT3360882T (pt)	2021-02-12
CY1122614T1 (el)	2020-07-31
EP3360881A1 (en)	2018-08-15
US20200297739A1 (en)	2020-09-24
EP3360882B1 (en)	2020-12-09
AU2014267324A1 (en)	2015-11-26
PE20200844A1 (es)	2020-08-18
EA201592055A1 (ru)	2016-11-30
MY187886A (en)	2021-10-26
RS57372B1 (sr)	2018-08-31
KR102229952B1 (ko)	2021-03-22

Publication	Publication Date	Title
IL272718B (en)	2020-11-30	History of 11-hydroxyl of bile acids and their conjugates with amino acid as paranoid x receptor modulators
SG11201604697TA (en)	2016-07-28	Membrane-penetrating peptides to enhance transfection and compositions and methods for using same
IL240727B (en)	2019-12-31	Peptides and compositions for the treatment of vertebral damage
IL235185A0 (en)	2014-12-31	mirna modulators of thermogenesis
IL237638A0 (en)	2015-04-30	Heteroaryl c17 derivatives of olanolic acid and methods of using them
IL227890A0 (en)	2014-01-30	Antiaging compounds containing bile acid and fatty acid conjugates
PL2814463T3 (pl)	2016-11-30	Okulistyczne kompozycje farmaceutyczne i sposoby ich wytwarzania i stosowania
EP2970928A4 (en)	2017-02-15	Generation of acyl amino acids
EP2819752A4 (en)	2016-03-09	USE OF MODULATORS OF CPT-1 AND ASSOCIATED COMPOSITIONS
EP3004132A4 (en)	2017-01-18	Bile acid-basic amino acid conjugates and uses thereof
ZA201503171B (en)	2016-11-30	Modified hyaluronic acid derivatives and use thereof
IL240734A0 (en)	2015-10-29	Methods and compositions for preparing nucleic acids
EP2808019A4 (en)	2015-06-10	IMPROVED NITAZOXANIDE COMPOSITION AND PROCESS FOR PREPARING THE SAME
TH1501006859A (th)	2017-07-27	อนุพันธ์ 11-ไฮดรอกซิลและกรดน้ำดีและสารควบคู่กรดอะมิโนของสิ่งนั้นในฐานะ ตัวควบคุมปรับสภาพฟาร์นีซอยด์ x รีเซพเตอร์
GB201202497D0 (en)	2012-03-28	Medicinal applications of substituted hydroxytetronic acids